SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Welcome to the POTP board, the DPP-IV company
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: former_pgs who wrote (8)8/4/2006 12:05:29 AM
From: rareearth42  Read Replies (1) of 90
 
Thanks f_pgs, very helpful.

For me, the comment that the CRs were durable is very important. One could imagine Talabostat decreasing the tumor-associated fibrosis, yielding an apparent decrease in size by CT and an apparent CR or PR, but no real effect on the malignant cells. However if this had happened, we wouldn't expect the clinical response to be durable, as the tumors should continue to grow. Accordingly, I remain enthusiastic about POTP.

RE42
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News